Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) breached their fiduciary duties in connection with the proposed sale of the Company to OPKO HEALTH, INC.

Additional Information:

Bio-Reference provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

On June 4, 2015, Bio-Reference announced it had signed a definitive merger agreement with OPKO. Under the terms of the transaction, holders of Bio-Reference common stock will receive 2.75 shares of OPKO common stock for each share of Bio-Reference common stock. Based on a closing price of $19.12 per share of OPKO common stock on June 3, 2015, the transaction is valued at approximately $52.58 per share of Bio-Reference common stock. Bio-Reference shareholders will be subject to the future price fluctuation of OPKO's stock price.

The investigation concerns whether Bio-Reference's board failed to satisfy their duties to the Company's shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for the Company's shares of common stock. Nationally recognized Johnson & Weaver, which focuses its practice on shareholder rights, is investigating whether the proposed deal price represents adequate consideration, especially given especially given Bio-Reference's promise of future growth.

If you are a shareholder of Bio-Reference and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ( ) at 619-814-4471. If emailing, please include a phone number where you can be reached.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

View source version on

Copyright Business Wire 2010